Teva Pharmaceutical Industries Limited, Clal Biotechnology Industries Raises Stake in Diabetes Treatment Developer, Andromeda; Teva and Clal to Invest $17.5 Million

June 14, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- Teva Pharmaceutical Industries has exercised an option to raise its stake in Andromeda Biotech, which is developing a treatment for juvenile Type I diabetes, Clal Biotechnology Industries said on Monday.

Twitter
LinkedIn
Facebook
Email
Print

Alliances